Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis
Main finding · MALO cumulative incidenceResult — go to the resultAdjusted hazard ratio 0.28 95% CI 0.12–0.64Authors' conclusion
Among patients with compensated MASH-related cirrhosis and obesity, metabolic surgery, compared with nonsurgical management, was associated with a significantly lower risk of incident MALO.
Study context
- Population
- Patients with obesity and compensated histologically proven MASH-related cirrhosismean follow-up 10.0 ± 4.5 years
- Participants
- 62 vs 106
- Exposure
- Metabolic surgery vs nonsurgical treatment
- Metabolic surgeryn = 62
- Nonsurgical controlsn = 106reference
- Outcome
- Time to incident major adverse liver outcomes (MALO)
- Follow-up
- 15 year cumulative incidence
Methodological detailsdoubly robust estimation
- Doubly robust estimation
Main finding
MALO cumulative incidence · 15 years
Adjusted hazard ratio
0.28
95% CI 0.12–0.64
P = 0.003
By group
Metabolic surgeryvs Nonsurgical controls
aHR 0.28 (95% CI 0.12–0.64); P = 0.003
As reported in the abstract
Observational data: associations, not effects.
Further findings
Decompensated cirrhosis, cumulative incidence · 15 years
- 15-year cumulative incidence in the surgical group
- 15.6% (95% CI, 0-31.3%)
- 15-year cumulative incidence in the nonsurgical group
- 30.7% (95% CI, 12.9-44.8%)
- Doubly robust estimation
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis. Nat Med. Published 27 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →